Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» MK-3475
MK-3475
Merck: Why Oncology Smells Like Money
Seeking Alpha
Mon, 11/4/13 - 09:49 am
Merck
oncology
Roche
Bristol-Myers Squibb
MK-3475
melanoma
Cancer immunotherapies turn a corner in race to megablockbuster market
Fierce Biotech
Wed, 10/2/13 - 10:54 am
cancer immunotherapy
Merck
MK-3475
nivolumab
Bristol-Myers Squibb
Roche
MPDL3280A
PDL-1
Merck drug triggers response in 24 pct of lung cancer patients
Yahoo/Reuters
Tue, 10/1/13 - 06:04 pm
Merck
MK-3475
lung cancer
3 Cancer Investing Opportunities
Seeking Alpha
Tue, 10/1/13 - 10:10 am
Merck
cancer
AstraZeneca
Bristol-Myers Squibb
MK-1775
ovarian cancer
MK-3475
melanoma
Yervoy
3 Things You Need to Know About This Big Pharma Deal
Motley Fool
Mon, 09/16/13 - 05:25 pm
Merck
AstraZeneca
MK-1775
MK-3475
Merck's lambrolizumab designated by the the FDA as Breakthrough Therapy
Yahoo/AP
Wed, 04/24/13 - 09:34 am
Merck
lambrolizumab
FDA
MK-3475
melanoma
Merck - How To Play This 'Patent Cliff' With Options
Seeking Alpha
Thu, 11/15/12 - 10:49 am
patent cliff
Merck
Singulair
Odanacatib
Maxalt
MK-3475
Pages
« first
‹ previous
1
2